Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients.
Santosh DhakalTong YuAnna YinNora PisanicZoe O DemkoAnnukka A R AntarAndrea L CoxChristopher D HeaneyYukari C ManabeSabra L KleinPublished in: Open forum infectious diseases (2022)
Antinucleocapsid (anti-N) immunoglobulin G antibody responses were lower in plasma and oral fluid after severe acute respiratory syndrome coronavirus 2 infection in vaccinated patients compared with patients infected before vaccination or infected without vaccination. This raises questions about the long-term use of anti-N antibodies as a marker for natural infection for surveillance.